Renal responses in a phase 1/2 study of at-02, a novel pan-amyloid depleter ig fusion protein for the treatment of patients with AL amyloidosis
Gregory Bell(Naples Anesthesia & Physician Associates), Ahmad Masri(Oregon Health & Science University), Brett W. Sperry(Saint Luke's Hospital), Brian Drachman(Penn Presbyterian Medical Center), Graham S. Hillis(The University of Western Australia), Vasvi Singh(HCA Midwest Division), Olga Motorna(The University of Melbourne), Matt Meldorf(Naples Anesthesia & Physician Associates), Claire D. Sherman(Naples Anesthesia & Physician Associates)
Cited by 2
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
|The Lancet|2015|984
Myocardial Injury after Noncardiac Surgery
|Anesthesiology|2014|979